title: Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
abstract: The incidences of infusion site adverse events in chemotherapy regimens, including anthracyclines with either fosaprepitant or aprepitant as the anti-emetic, were not highlighted in the randomized trial comparing aprepitant and fosaprepitant. The present retrospective analysis was performed in breast cancer patients receiving anthracycline-containing chemotherapy, a combination of epirubicin and cyclophosphamide with or without 5-fluorouracil as the adjuvant or neoadjuvant, at the outpatient infusion center of St. Marianna University Hospital (Kawasaki, Japan). Infusion site adverse events were retrospectively compared between the 3 months prior to and three months following switching from 3 day oral administration of aprepitant to intravenous infusion of fosaprepitant. A total of 62 patients were included in the aprepitant group and 38 in the fosaprepitant group. Of these patients, 26 (42%) in the aprepitant group and 36 patients (96%) in the fosaprepitant group experienced any grade of infusion site adverse events at least once (P<0.001). As an anti-emetic treatment for chemotherapy using anthracyclines, fosaprepitant may be associated with a higher risk of infusion site adverse events compared with aprepitant.
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Tsuda
authors.affiliation: Department of Nursing, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Chisato
authors.initials: C
authors.lastname: Kyomori
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Takuro
authors.initials: T
authors.lastname: Mizukami
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Taniyama
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Izawa
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Horie
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Mami
authors.initials: M
authors.lastname: Hirakawa
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogura
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Takako Eguchi
authors.initials: TE
authors.lastname: Nakajima
authors.affiliation: Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Tsugawa
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
keywords: anthracyclines; fosaprepitant; infusion site adverse events